WO2013183985A1 - Procédé de traitement d'un trouble cognitif et composés pour l'utiliser - Google Patents

Procédé de traitement d'un trouble cognitif et composés pour l'utiliser Download PDF

Info

Publication number
WO2013183985A1
WO2013183985A1 PCT/NL2012/050391 NL2012050391W WO2013183985A1 WO 2013183985 A1 WO2013183985 A1 WO 2013183985A1 NL 2012050391 W NL2012050391 W NL 2012050391W WO 2013183985 A1 WO2013183985 A1 WO 2013183985A1
Authority
WO
WIPO (PCT)
Prior art keywords
nfl
mice
hcn channel
channel agonist
hcn
Prior art date
Application number
PCT/NL2012/050391
Other languages
English (en)
Inventor
Ype ELGERSMA
Steven Aaron KUSHNER
Original Assignee
Erasmus University Medical Center Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus University Medical Center Rotterdam filed Critical Erasmus University Medical Center Rotterdam
Priority to PCT/NL2012/050391 priority Critical patent/WO2013183985A1/fr
Publication of WO2013183985A1 publication Critical patent/WO2013183985A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne le traitement, la prévention ou l'amélioration d'un trouble cognitif chez un sujet, comprenant l'administration audit sujet d'une quantité thérapeutiquement efficace d'un agoniste de canal activé par l'hyperpolarisation modulé par les nucléotides cycliques (HCN), de préférence, la lamotrigine.
PCT/NL2012/050391 2012-06-05 2012-06-05 Procédé de traitement d'un trouble cognitif et composés pour l'utiliser WO2013183985A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/NL2012/050391 WO2013183985A1 (fr) 2012-06-05 2012-06-05 Procédé de traitement d'un trouble cognitif et composés pour l'utiliser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2012/050391 WO2013183985A1 (fr) 2012-06-05 2012-06-05 Procédé de traitement d'un trouble cognitif et composés pour l'utiliser

Publications (1)

Publication Number Publication Date
WO2013183985A1 true WO2013183985A1 (fr) 2013-12-12

Family

ID=46321421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2012/050391 WO2013183985A1 (fr) 2012-06-05 2012-06-05 Procédé de traitement d'un trouble cognitif et composés pour l'utiliser

Country Status (1)

Country Link
WO (1) WO2013183985A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602017A (en) 1979-06-01 1986-07-22 Sawyer David A Substituted aromatic compounds
US5134127A (en) 1990-01-23 1992-07-28 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO2002002630A2 (fr) * 2000-07-03 2002-01-10 Smithkline Beecham P.L.C. Nouvelles utilisations
WO2002050300A2 (fr) * 2000-12-20 2002-06-27 Merck & Co., Inc. Hcn3 de canal cationique declenche par des nucleotides cycliques et actives par hyperpolarisation chez l'homme
WO2008095221A1 (fr) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Traitement du syndrome hypercinétique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602017A (en) 1979-06-01 1986-07-22 Sawyer David A Substituted aromatic compounds
US5134127A (en) 1990-01-23 1992-07-28 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO2002002630A2 (fr) * 2000-07-03 2002-01-10 Smithkline Beecham P.L.C. Nouvelles utilisations
WO2002050300A2 (fr) * 2000-12-20 2002-06-27 Merck & Co., Inc. Hcn3 de canal cationique declenche par des nucleotides cycliques et actives par hyperpolarisation chez l'homme
WO2008095221A1 (fr) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Traitement du syndrome hypercinétique

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
AKHONDZADEH S ET AL: "Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?", THERAPY 200505 GB, vol. 2, no. 3, May 2005 (2005-05-01), pages 399 - 406, XP008160169, ISSN: 1475-0708 *
COSTA ET AL., NATURE, vol. 415, 2002, pages 526 - 530
CUI ET AL., CELL, vol. 135, 2008, pages 549 - 560
FLEISHER ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 19, 1996, pages 115
H. BUNDGAARD, DRUGS OF THE FUTURE, vol. 16, 1991, pages 443
KHAN ARIFULLA ET AL: "Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder.", THE JOURNAL OF CLINICAL PSYCHIATRY NOV 2004, vol. 65, no. 11, November 2004 (2004-11-01), pages 1483 - 1490, XP008160172, ISSN: 0160-6689 *
LI ET AL., CURR BIOL, vol. 15, 2005, pages 1961 - 1967
M. BIEL ET AL: "Hyperpolarization-Activated Cation Channels: From Genes to Function", PHYSIOLOGICAL REVIEWS, vol. 89, no. 3, 1 July 2009 (2009-07-01), pages 847 - 885, XP055053117, ISSN: 0031-9333, DOI: 10.1152/physrev.00029.2008 *
MAGEE, NAT NEUROSCI, vol. 2, 1999, pages 508 - 514
NOLAN ET AL., CELL, vol. 119, 2004, pages 719 - 732
PENG ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 35, 2010, pages 464 - 472
POOLOS ET AL., NAT NEUROSCI, vol. 5, 2002, pages 767 - 774
PRESSLER R M ET AL: "Effect of lamotrigine on cognition in children with epilepsy.", NEUROLOGY 23 MAY 2006, vol. 66, no. 10, 23 May 2006 (2006-05-23), pages 1495 - 1499, XP008160171, ISSN: 1526-632X *
R. KUMAR, M., J PHARM PHARMACEUT SCI., vol. 3, no. 2, 2000, pages 234 - 258
SHAH ET AL., NEURON, vol. 44, 2004, pages 495 - 508
SHILYANSKY ET AL., ANNU REV NEUROSCI., vol. 33, 2010, pages 221 - 43
SHILYANSKY ET AL., PROC. NAT. ACAD. SCI., vol. 107, 2010, pages 13141 - 13146
SILVA ET AL., CLIN NEUROSCI RES, vol. 1, 2001, pages 187 - 193
SILVA ET AL., NAT GENET, vol. 15, 1997, pages 281 - 284
THIJS VAN DER VAART: "FROM MOUSE MODELS TO CLINICAL TRIALS; OPPORTUNITIES FOR COGNITIVE GENETIC DISORDERS", NEUROBIOLOGY OF LEARNING AND MEMORY, 3RD PF2MUC SYMPOSIUM, 25 January 2013 (2013-01-25), XP055053375, Retrieved from the Internet <URL:http://www.uc.pt/en/fmuc/pf2muc/3rdSymposium/PROGRAM_v3.pdf> [retrieved on 20130214] *
VAN DER VAART ET AL., GENES BRAIN BEHAV, vol. 10, 2011, pages 404 - 409
WULFF ET AL., PNAS, vol. 106, no. 9, 2009, pages 3561 - 3566

Similar Documents

Publication Publication Date Title
Bennett et al. The role of voltage-gated sodium channels in pain signaling
Dell'Orco et al. Neuronal atrophy early in degenerative ataxia is a compensatory mechanism to regulate membrane excitability
Kostich et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain
Patrizi et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype
Brandon et al. Defective motor behavior and neural gene expression in RIIβ-protein kinase A mutant mice
Wallace et al. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease
Weng et al. Rett syndrome: from bed to bench
US20230031479A1 (en) Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
Xiao et al. Deletion of adenosine A1 or A2A receptors reduces L-3, 4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
Schulz et al. Enhanced dendritic inhibition and impaired NMDAR activation in a mouse model of down syndrome
Bazyan et al. Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures
Yamada et al. Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats
Joshi et al. Infantile spasms in Down syndrome: rescue by knockdown of the GIRK2 channel
Longaretti et al. LSD1 is an environmental stress-sensitive negative modulator of the glutamatergic synapse
JP2017119722A (ja) タウ凝集阻害剤
WO2013183985A1 (fr) Procédé de traitement d&#39;un trouble cognitif et composés pour l&#39;utiliser
CN115006534B (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
Oksman et al. Behavioural and neurochemical response of α-synuclein A30P transgenic mice to the effects of L-DOPA
WO2008157753A1 (fr) Procédés de traitement d&#39;une atrophie musculaire spinale
Etievant et al. Partial dopamine D2/serotonin 5-HT1A receptor agonists as new therapeutic agents
Kodirov Adam, amigo, brain, and K channel
Pérez-Torres Retromer deficiency in amyotrophic lateral sclerosis
Yang Central Amygdala-Associated Behavioural Phenotypes in a Gain-Of-Function Voltage-Gated Sodium Channel NaV1. 5 Mouse Model
Kurita et al. Novel Targets for Drug Treatment in Psychiatry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12728841

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12728841

Country of ref document: EP

Kind code of ref document: A1